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ABSTRACT
The relationship between DNA topoisomerase II activity and drug
resistance was studied in cloned cell lines of Adriamycin (ADR)-sensitive
and -resistant P388 leukemia; drug resistant P388/ADR/3 (clone 3) and
P388/ADR/7 (clone 7) cells are 5- and 10-fold more resistant to ADR
than the sensitive cell line P388/4 (Cancer Res., 46: 2978, 1986). Topo
isomerase II catalytic activity in crude nuclear extracts was reduced in
drug-resistant cells as determined qualitatively by decatenation of kDNA.
Using the centrifugal method of quantitative analysis, topoisomerase II
catalytic activity (mean Â±SE) was 81 Â±10 units/mg total nuclear protein
in sensitive cells, 29 Â±2 units/mg total nuclear protein in resistant clone
3 cells, and 16 Â±2 units/mg total nuclear protein in resistant clone 7
cells; these differences were highly significant (P < 0.005). Similarly,
quantitative analysis of DNA cleavage activity using 3' "P-end-labeled
pBR322 restriction fragments showed that drug-stimulated topoisomer
ase II cleavage activity in nuclear extracts from sensitive cells was
approximately 1.7- and 2.9-fold greater than that from resistant clone 3
and 7 cells, respectively. Western blot analysis of nuclear extracts from
the three cell lines using antibody against the ("-terminal half of recom-
binant-prepared human topoisomerase II polypeptide revealed reduced
intmunoreactivity of topoisomerase II protein in the drug-resistant cells.
These data suggest that reduced topoisomerase II activity in resistant
cells, which may represent quantitative reduction of the enzyme, may be
another property contributing to multifactorial drug resistance in these
cells.
INTRODUCTION
Mammalian DNA topoisomerase types I and II are nuclear
enzymes that have been proposed to function in a variety of
genetic processes and induce topologica! changes of DNA (for
reviews, see References 1-4). The type II topoisomerases are
ATP-dependent enzymes that catalyze the topologica! passing
of two double-stranded DNA segments, presumably by intro
ducing a transient enzyme-linked double strand break in one of
the passing strands (5-9). This strand passing or catalytic
activity of topoisomerase II can be assayed in vitro by ATP-
dependent relaxation of supercoiled DNA, knotting/unknotting
of P2 and P4 DNA, or catenation/decatenation of kDNA3 (5,
6, 10-17). Topoisomerase II activity can also be assayed by
measuring enzyme-mediated drug-induced cleavage of appro
priate DNA substrates (18, 19). An important feature of topo
isomerase II-mediated activity is the formation of a covalent
bond between a tyrosyl residue on the enzyme and the phos
phate moiety at the 5 ' terminus of the DNA at the break site,
thereby creating an intermediate DNA-enzyme complex re
ferred to as the "cleavable complex" (18, 20-22).
Several antitumor agents have been postulated to inhibit
topoisomerase II activity including DNA intercalators such as
Adriamycin and 4'-(9-acridinylamino)methanesulfon-/n-anisi-
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dide and epipodophyllotoxins such as etoposide and teniposide
(21, 23-26). Evidence has accumulated to suggest that these
drugs interact with topoisomerase II to stabilize the "cleavable
complex" resulting in increased DNA scission and inhibition
of the rejoining reaction (1, 22, 24, 26); in the presence of
protein denaturing agents, the enzyme is trapped in this form
which may be observed experimentally as protein-associated
DNA strand breaks when assayed by filter elution technology
(27-30). It follows that the extent of DNA double-strand breaks
induced by topoisomerase-interacting drugs is a function of the
levels of topoisomerase II activity as well as the quality of
interaction of drug with the enzyme or enzyme-DNA complex.
There are several reports in the literature that implicate reduced
topoisomerase II activity in the drug resistance phenotype (19,
31-37).
The findings presented here are an extension of two previous
reports (38, 39) that have defined the multifactorial nature of
drug resistance in cloned cell lines of ADR-sensitive and
-resistant P388 leukemia. Among those contributory factors
reported, we showed previously (38) that resistance in these
cells can be attributed in part to reduced levels of drug-induced
double strand breaks. Here, we report that crude nuclear ex
tracts of ADR-resistant P388 cells show markedly reduced
levels of topoisomerase II catalytic activity as compared to
drug-sensitive cells. In addition, drug-induced topoisomerase
II-mediated cleavage of DNA in the crude nuclear extracts was
also substantially reduced in the resistant cell lines. The de
crease in enzyme activity correlated with reduced immunoreac-
tivity of the topoisomerase II protein as determined by Western
blot analysis using a specific antibody. These results are dis
cussed in view of the role of topoisomerase II as a target for
the cytotoxic action of ADR.
MATERIALS AND METHODS
Cell Lines and Cultures. Cloned lines of ADR-sensitive (P388/4) and
-resistant (P388/ADR/3 or clone 3 and P388/ADR/7 or clone 7)
leukemia cells (38) were maintained in vivo by weekly transplantation
of an inoculum of IO6 cells i.p. in 6-8-week-old female DBA/2 mice.
Clone 3 and clone 7 cells are 5- and 10-fold more resistant to ADR
than the drug-sensitive cells and the resistant phenotype is stable for at
least 1 year. Suspension cultures in vitro were maintained by growing
the cells in the absence of drug in RPMI medium supplemented with
15% fetal bovine serum (Grand Island Biological Co., Grand Island,
NY). Both sensitive and resistant cells used in these experiments grew
exponentially with a doubling time of 11 to 12 h.
Drugs and Chemicals. ADR was obtained from Adria Laboratories,
Columbus, OH. [3H]Thymidine (specific activity, 50-80 Ci/mmol) was
obtained from New England Nuclear, Boston, MA.
Preparation of DNA Substrates. kDNA was prepared from the try-
panosome Crithidia fasciculata (purchased from Carolina Biological
Supply Co., Burlington, NC). Cultures were grown on a rotary shaker
for 72 h at 27Â°Cin trypticase peptone medium supplemented with
hem in (10 Â¿ig/ml)and liver extract (0.1 mg/ml). For preparation of
kDNA labeled with 3H, cultures were grown in the presence of 5 mCi/
liter of (m<'//nV'I I|lhymidirie. Stationary phase cells at about 1 x 10s
cells/ml were harvested and kDNA was isolated from sarkosyl extracts
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of the cells by cesium chloride-ethidium bromide density gradient
centrifugation as previously described (11, 16).
Supercoiled plasmici pBR322 dimer was prepared from Escherichia
coli strain HB101 by standard procedures (10, 40, 41). ///Will-linear
ized pBR322 DNA was end-labeled at the 3'-end by treatment with the
Klenow fragment, [32P]dATP and unlabeled dCTP, dGTP, and TTP
for 30 min at 25Â°Cas described previously (18, 19). Unincorporated
triphosphates were separated from labeled DNA by gel filtration
through a Sephadex G-50 column equilibrated in 0.5 M NaCl, 50 mM
tris-Cl (pH 7.7), and 0.5 mM EDTA. Labeled DNA samples were
concentrated by ethanol precipitation.
Preparation of Crude Nuclear Extracts. Crude nuclear extracts were
prepared by a modification of a published report (30). Exponentially
growing cells were collected by centrifugation and washed in ice-cold
NB (NB consists of 2 mM K2HPO4, 5 mM MgCl2, 150 mM NaCl, 1
mM EGTA, and 0. l mM dithiothreitol, pH adjusted to 6.5). The washed
cells were resuspended in NB and 9 ml of NB supplemented with 0.35%
Triton X-100 and 1 mM phenylmethylsulfonyl fluoride were added
slowly down the side of the tube. The cell suspension was mixed by
rotation for 5 min at 4Â°C,centrifuged at 1000 x g for 10 min, and the
nuclear pellet washed in Triton-free NB. Nuclear protein was extracted
from the nuclei for 30 min at 4Â°Cwith ice-cold NB containing 0.35 M
NaCl. DNA and nuclear debris were pelleted by centrifugation at 17,000
x g for 10 min and the supernatant collected. Protein concentration in
the extract was determined by the method of Bradford (42). Extracts
were adjusted to a protein concentration of 20 ng/Vl. Glycerol was
immediately added to a final concentration of 50%.
Assay of Catalytic Activity of DNA Topoisomerase II. The standard
reaction mixture for all types of topoisomerase II assays contained 50
mM tris-Cl (pH 8), 10 mM MgCl2, 5 mM dithiothreitol, 0.5 mM EDTA,
10 /Â¿g/mlof bovine serum albumin, and l mM ATP, pH 7.7. The
reaction mixture had a final NaCl concentration of 70 mM and a final
glycerol concentration of 10% (both components contributed by the
nuclear extract).
Topoisomerase II catalytic activity was assayed by decatenation of
kDNA into free minicircles. Two types of analysis were performed: a
centrifugal analysis in which [3H]kDNA was used as substrate and free
minicircles were separated from kDNA by a brief centrifugation; and
an electrophoretic analysis in which unlabeled kDNA was used as
substrate and minicircles were resolved by gel electrophoresis (7, 17,
43). For both types of analysis, decatenation was carried out by incu
bating 10 n\ of nuclear extract (containing 200 ng total protein) with 2
Mgof kDNA in a final volume of 50 n\ of reaction mixture at 30Â°Cfor
30 min. A time course of enzyme activity using the centrifugal method
was linear for at least 40 min for ADR-sensitive and -resistant cell lines
(data not shown). At the end of the reaction, samples analyzed by the
centrifugal method were treated with 5 n\ of 2.25% SDS, centrifuged
at 13,000 x g for 5 min in a table top microcentrifuge, and the
supernatant collected for determining radioactivity by scintillation
counting. The results were quantitated by converting the radioactivity
liberated in the supernatant to amount of DNA (ng) by using the
specific activity of [3H]kDNA. Samples analyzed by gel electrophoresis
were treated with 5 M' of a dye solution consisting of 5% SDS, 50%
glycerol, and 0.25 mg/ml bromophenol blue; samples were then elec-
trophoresed through 1% agarose in 90 mM tris-borate-2 mM EDTA
(pH 8.0) at 25 v for 20 h. After staining with ethidium bromide (5 ng/
ml) gels were photographed under UV.
Assay of Cleavage Activity of DNA Topoisomerase II. Topoisomerase
11drug-stimulated DNA cleavage activity was assayed qualitatively by
the generation of linearized (form III) from supercoiled (form I)
pBR322 DNA in a final volume of 50 p\ of reaction mixture for 15
min at 37Â°Cas described previously (19). The reaction was terminated
by the addition of the dye solution described above and the samples
analyzed by electrophoresis through 1% agarose as described for the
decatenation assay. The electrophoresis running buffer contained 0.1 %
SDS in order to dissociate the intercalati>r (ADR) molecules from DNA
(44). Gels were washed three times with water to remove SDS, stained
with ethidium bromide (5 fig/ml), destained in water and photographed
under UV.
Quantitative analysis of DNA cleavage activity of topoisomerase II
was assayed using 3' 32Pend-labeled pBR322 restriction fragments and
the SDS-KC1 precipitation of topoisomerase II-DNA complexes as
described previously (18, 19).
SDS-Polyacrylamide Gel Electrophoresis and Western Blotting. Nu
clear extracts from sensitive and resistant cells were electrophoresed on
a 5-10% gradient polyacrylamide gel according to the procedure of
Laemmli (45). Proteins from the gel were electrotransferred onto a
nitrocellulose sheet by Towbin's method (46) using an LKB-Nova blot
apparatus. The blot was incubated overnight at 37Â°Cwith blocking
buffer [3% bovine serum albumin in 10.5 mM tris-HCl (pH 7.5)-175
HIM NaCl] followed by incubation with polyclonal rabbit antiserum
against recombinant human topoisomerase II polypeptide (C terminal
half), which was kindly provided by Dr. Leroy Liu, in fresh blocking
buffer for 16 h at 0Â°C.At the end of incubation, the blot was washed
with tris-saline buffer and incubated with alkaline phosphatase-conju-
gated goat anti-rabbit IgG at room temperature for 5 h. Bands were
visualized after washing the blot with tris-saline buffer and incubating
with substrate for alkaline phosphatase as described by the supplier
(Bethesda Research Laboratory, Gaithersburg, MD).
RESULTS
Catalytic Activity of DNA Topoisomerase II in Adriamycin-
sensitive and -resistant P388 Leukemia
Catalytic activity of DNA topoisomerase II in nuclear ex
tracts of P388 cell lines was assayed by decatenation of kDNA,
and separation by gel electrophoresis of kDNA and free mini-
circles (Fig. 1). In the absence of nuclear extract, kDNA (k) is
seen as a slow-moving band close to the well (Lane C). When
nuclear extract is added to kDNA, decatenation occurs and free
minicircles (m) are observed as a fast-moving band away from
the well. The intensity of fluorescence observed indicates that
more DNA minicircles are liberated with nuclear extract from
drug-sensitive P388/4 cells than that from either of the two
resistant clones. The amount of minicircles liberated is a meas
ure of the activity of topoisomerase II in the nuclear extract.
Quantitation of topoisomerase II catalytic activity using the
centrifugal method of Sahai and Kaplan (17) was performed(Table 1). Using [3H]kDNA as substrate, topoisomerase II
catalytic activity (mean Â±SE) was 81 Â±10 units/mg total
nuclear protein in sensitive cells, 29 Â±2units/mg total nuclear
1
m
Fig. 1. Decatenation of kDNA by nuclear extracts from sensitive and resistant
clone 3 and 7 cells. Decatenation reaction was carried out as described in the
text. Reaction mixture was incubated in the absence of nuclear extract (Lane C)
or in the presence of nuclear extract (containing 200 ng total protein) from ADR-
sensitive P388/4 cells (Lane 1), or drug-resistant clones 3 and 7 (Lanes 2 and 3,
respectively), k, kDNA band; m, free minicircles. Protein concentration in the
extracts from all three cell lines was equivalent.
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Table l Catalytic activity of topoisomerase 11 in nuclear extracts of
ADR-sensitive and -resistant P388 leukemia
Topoisomerase II catalytic activity*
(units/mg total nuclear protein)
Experiment'11
2
3
Mean Â±SEP388/461e
97
84
81 Â±10P388/ADR/329
3325
29 Â±2P388/ADR/716
191316Â±2
" Each experiment was performed with fresh nuclear extract prepared from
exponentially growing cells in mid-log phase. Glycerol was added to a final
concentration of 50% to each sample.
* Topoisomerase II catalytic activity was assayed quantitatively by the centrif
ugal method as described in "Materials and Methods." One unit of enzyme is
defined as the amount that catalyzes the release of 400 ng of DNA into the
supernatant as free minicircles in 30 min at 30'C.
' Units of enzyme activity for each experiment is a mean of four determinations.
P388/4 P388/ADR/7
C O 2 5 10 20 50100 C O 2 5 10 20 50 100
Fig. 2. ADR-induced cleavage activity of DNA topoisomerase II in crude
nuclear extracts from drug-sensitive and -resistant P388 leukemia cells. The DNA
cleavage assay was performed as described in the text. Lane C, control in which
the reaction mixture containing supercoiled pBR322 was incubated without
nuclear extract or drug. Numbers, ADR concentration in micromolar units.
Extract dose was 10 n\ (200 ng total nuclear protein) in a final volume of 50 n\.
The various topologica! isomers of pBR322 are marked / (super-coiled), // and
//' (relaxed and/or nicked), and ///(linear) forms.
protein in resistant clone 3 cells, and 16 Â±2 units/mg total
nuclear protein in resistant clone 7 cells; these differences were
highly significant (P < 0.005). Hence catalytic activity of to
poisomerase II varies directly with sensitivity to the intercalator
ADR.
Cleavage Activity of DNA Topoisomerase II in Adriamycin-
sensitive and -resistant P388 Leukemia
Drug-mediated cleavage activity of DNA topoisomerase II in
crude nuclear extracts of ADR-sensitive and -resistant cells was
measured (Fig. 2). In the absence of nuclear extract and ADR,
pBR322 DNA migrates predominantly in the fast-moving su
percoiled state (form I). Addition of nuclear extract without
drug results in conversion of supercoiled pBR322 DNA (form
I) into the relaxed and/or nicked configurations (forms II and
II'). Linearized DNA (form III) is generated when ADR is
added in the presence of nuclear extract. Linearized DNA first
appears with extracts from sensitive cells at ADR concentra
tions as low as 5-10 Â¿Â¿M,whereas with nuclear extracts from
drug-resistant cells, the corresponding drug concentration is 50
to 100 MMdrug (Fig. 2).
Topoisomerase II cleavage activity in nuclear extracts of
P388 cells was quantitated by precipitation of drug-stabilized
DNA-protein complexes with SDS-KC1 solution (Fig. 3). In
this assay, topoisomerase II in nuclear extracts forms a covalent
linkage with the 5'-end of linearized pBR322 DNA that is
labeled with [32P]dATP at its 3' end; in the presence of ADR,
this topoisomerase II-DNA complex is stabilized and may be
precipitated by addition of SDS-KC1 solution. The results in
Fig. 3 show that a greater amount of 32P-labeled DNA was
precipitated with nuclear extract from sensitive cells than that
from either of the two resistant cell lines. A comparison of
ADRIAMYCIN
Fig. 3. Quantitative assay of the cleavage activity of DNA topoisomerase II in
ADR-sensitive and -resistant P388 leukemia cells. Effect of ADR on the level of
32P-labeled DNA precipitated by SDS and KC1solution in the presence of nuclear
extracts of sensitive P388/4 cells (O), resistant clone 3 cells (â€¢),and resistant
clone 7 cells (D)- 3' 32P end-labeled pBR322 restriction fragment was incubated
in a final volume of 50 j<lwith 200 ng total protein nuclear extract and varying
concentrations of ADR for 15 min at 37Â°C.At the end of the incubation period,
stable DNA-protein complexes were precipitated with SDS-KC1 solution as
described (18, 19). The amount (cpm) of "P-labeled DNA precipitated relative
to control level observed in the absence of ADR is plotted against ADR concen
tration. Inset, amount (cpm) of 32P-labeled DNA precipitated relative to control
over the initial linear phase of the dose-response curve. The linear regression
equation of the plot for sensitive P388/4 cells was y = 3.13* + 1.55 with a
correlation coefficient of 0.988, that for resistant clone 3 cells was y = 1.82* +
0.95 with a correlation coefficient of 0.994, and that for resistant clone 7 cells
was y = 1.07* + 0.82 with a correlation coefficient of 0.987.
slopes from the initial linear portion of the curves shows that
enzyme activity from sensitive cells was approximately 1.7- and
2.9-fold greater than that from resistant clone 3 and 7 cells,
respectively (Fig. 3, inset).
Detection of Topoisomerase II by Western Blot Analysis
The amount of DNA topoisomerase II in the three cell types
was determined by Western blotting using rabbit antiserum to
the C-terminal half of recombinant prepared human topoisom
erase II polypeptide (Fig. 4). A marked reduction in the level
of topoisomerase II homodimer subunit (Mr 170,000) was de
tected in resistant clone 3 and 7 cells compared to sensitive
P388/4 cells.
DISCUSSION
In this extension of our previous reports (38, 39) we have
compared DNA topoisomerase II activity and enzyme content
in the three cell lines which differ in their level of sensitivity to
the intercalator ADR. The model system that we have used in
our studies of mechanism of drug resistance is particularly
useful for two reasons: firstly, these are cloned cell lines, so
that the various factors contributing to resistance cannot be
attributed to different cell subpopulations, and secondly, the
use of two resistant cell lines which differ in their degree of
resistance, permits quantitative comparisons of various bio
chemical and molecular features. In addition, the relatively
modest levels of resistance in our cells are probably more
relevant clinically than that of other systems characterized by
much higher levels of drug resistance.
Since DNA topoisomerase II has been identified as an intra-
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1
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Fig. 4. Western blot analysis of topoisomerase II Â¡nuclear extracts of ADR-
sensitive and -resistant P388 leukemia cells. Proteins were separated on a 5-10%
gradient gel as described in the text. Each lane was loaded with nuclear extract
(50 ng protein) from P388 cells. Nuclear extracts from sensitive P388/4, resistant
clone 3 and clone 7 cells were loaded on Lanes 1-3, respectively.
cellular target for certain antineoplastic agents (22,47), a study
of catalytic and cleavage activity was undertaken in ADR-
sensitive and -resistant P388 leukemia cells. Qualitative assays
of both catalytic and cleavage activity of DNA topoisomerase
II were markedly reduced in ADR-resistant cells (Fig. 1 and 2).
Other cellular factors such as nucleases in the crude extract
may influence DNA catalytic and cleavage activity. However,
the reaction conditions tended to minimize nuclease activity, as
reported previously (17). Furthermore, linear DNA (form III)
was not observed in the drug-sensitive and -resistant cells in the
presence of crude nuclear extract without ADR (Fig. 2, Lane
0). Quantitative assays revealed a direct correlation between
drug sensitivity and enzyme activity; catalytic activity was re
duced 2.8- and 5-fold in resistant clone 3 and 7 cells respectively
(Table 1), whereas cleavage activity was correspondingly re
duced 1.7- and 2.9-fold (Fig. 3). These findings are consistent
with a report of decreased topoisomerase II activity in amsa-
crine-resistant P388 leukemia cells (48).
The decrease in topoisomerase II activity reported here cor
relates closely with the lower levels of DNA strand breaks
previously reported in ADR-resistant cells (38). There is grow
ing evidence that drug-induced DNA strand breaks, measured
by filter elution technology, are mediated by topoisomerase II
(27-30). A number of investigators have suggested involvement
of topoisomerase II in the resistance of various cell lines to
intercalating drugs and epipodophyllotoxins by correlating drug
resistance with reduced levels of protein-associated DNA strand
breaks (31, 33-35). Another report has shown that Chinese
hamster ovary cell mutants that are hypersensitive to topoisom
erase II interacting drugs exhibit enhanced levels of DNA strand
breaks (36).
The reduction in catalytic and cleavage activity of topoisom
erase II in resistant cells may represent either a quantitative or
qualitative change in the enzyme. Western blot analysis of
nuclear extracts from the three cell lines using antibody against
the C-terminal half of recombinant prepared human topoisom
erase II polypeptide showed a lower intensity of staining of a
protein band of 170,000 molecular weight in the drug-resistant
cells (Fig. 4). This protein band is in the same molecular weight
range as that observed by other investigators for topoisomerase
II in various mammalian cells (7, 48-50). Our findings are in
agreement with those of Drake et al. (48), who reported a lower
level of the M, 170,000 protein in amsacrine-resistant P388
leukemia cells, and may be explained by a quantitative reduction
of DNA topoisomerase II in ADR-resistant cells. However, this
study does not exclude the possibility of posttranslational mod
ifications or other qualitative changes of the protein resulting
in both decreased enzyme activity and immunoreactivity.
Other studies have also invoked a role for DNA topoisom
erase II in drug resistance (19, 32, 37,48). However, previously
greater emphasis has been placed on cleavage rather than cat
alytic activity as an index of cytotoxicity (19). In Chinese
hamster ovary cells resistant to etoposide (VP-16) decreased
cleavage activity of topoisomerase II but with no alteration of
catalytic function was reported (19). In this study with ADR-
resistant P388 cells, not only cleavage but also catalytic activity
was reduced in resistant cells. This apparent discrepancy might
represent different mechanisms of resistance for different drugs
or might simply reflect differences between cell lines. The data
presented here, showing decreased levels of topoisomerase II
activity in ADR-resistant P388 leukemia cells suggest that
reduction in topoisomerase II may be another property contrib
uting to multifactorial drug resistance in these cells.
ACKNOWLEDGMENTS
We thank Dr. Leroy Liu for the polyclonal antibody against recom
binant prepared human DNA topoisomerase II, Dr. Beni Sahai for
helpful discussions and initial supplies of kDNA and Glenys Morgan
for typing the manuscript.
REFERENCES
1. Liu, L. F. DNA topoisotnerasesâ€”enzymes that catalyse the breaking and
rejoining of DNA. CRC Crit. Rev. Biochem., IS: 1-24, 1983.
2. Wang, J. C. DNA topoisomerases. Ann. Rev. Biochem., 54: 665-697, 1985.
3. Vosberg, H. P. DNA topoisomerases: Enzymes that control DNA confor
mation. Curr. Top. Microbiol. Immumd,, 114: 19-102, 1985.
4. Maxwell, A., and Geliert, M. Mechanistic aspects of DNA topoisomerases.
Adv. Protein Chem., 38:69-107, 1986.
5. Liu, L. F., Liu, C. C., and Alberts, B. M. Type II DNA topoisomerases:
Enzymes that can unknot a topologically knotted DNA molecule via revers
ible double-strand break. Cell, 19: 697-707, 1980.
6. Hsieh, T., and Brutlang, D. ATP-dependent DNA topoisomerase from D.
melanogaster reversibly catenates duplex DNA rings. Cell, 21: 115-125,
1980.
7. Miller, K. G., Liu, L. F., and Englund, P. T. A homogeneous type II DNA
topoisomerase from HeLa cell nuclei. J. Biol. Chem., 256:9334-9339,1981.
8. Ambreski, K., Wierzbicki, A., Frommer, B., and Hoess, R. H. Bacteriophage
PI Cre-loxP site-specific recombination. Site-specific DNA topoisomerase
activity of the Cre recombination protein. J. Biol. Chem., 261: 391-396,
1986.
9. Osheroff, N. Eukaryotic topoisomerase II. Characterisation of enzyme turn
over. J. Biol. Chem., 261:9944-9950, 1986.
10. Clewell, D. B. Nature of Col E, plasmid replication in Escherichia colt in the
presence of chloramphenicol. J. Bacteriol., 10: 667-676, 1972.
11. Simpson, L. Isolation of maxicircle component of kinetoplast DNA from
hemoflagellate protozoa. Proc. Nati. Acad. Sci. USA, 76: 1585-1588, 1979.
12. Borst, P., and Hoeijmaker, J. H. J. Kinetoplast DNA. Plasmid, 2: 20-40,
1979.
13. Liu, L. F., Davis, J. L., and Calendar, R. Novel topologically knotted DNA
from bacteriophage P4 capsids: studies with DNA topoisomerases. Nucleic
Acids Res., 9: 3979-3989, 1981.
14. Liu, L. F., Perkocha, L., Calendar, R., and Wang, J. C. Knotted DNA from
bacteriophage capsids. Proc. Nati. Acad. Sci. USA, 78: 5498-5502, 1981.
15. Baldi, M. I., Benedetti, P., Mattocia, E., and Tocchini-Valentini, G. P. In
vitro catenation and decatenation of DNA and a novel eukaryotic ATP-
dependent topoisomerase. Cell, 20: 461-467, 1980.
16. Hadjuk, S. L., Klein, V. A., and Englund, P. T. Replication of kinetoplast
DNA maxicircles. Cell, 36:483-492, 1984.
17. Sahai, B. M., and Kaplan, J. G. A quantitative decatenation assay for type II
topoisomerases. Anal. Biochem., 156: 364-379, 1986.
18. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. Cleavage
of DNA by mammalian DNA topoisomerase II. J. Biol. Chem., 258:15365-
15370, 1983.
19. Glisson, B., Gupta, R., Smallwood-Kentro, S., and Ross, W. Characterisation
61
DNA TOPOISOMERASE II AND CYTOTOXICITY
of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell
line: loss of drug-stimulated DNA cleavage activity. Cancer Res., 46: 1934-
1938, 1986.
20. Sander, M., and Hsieh, T. S. Double-stranded DNA cleavage of type II DNA
topoisomerase from Drosophila melanogaster. J. Biol. Chem., 258: 8421-
8428, 1983.
21. Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. Intercalate
antitumor drugs interfere with the breakage-reunion reaction of mammalian
DNA topoisomerase II. J. Biol. Chem., 259: 9182-9187, 1984.
22. Ross, W. E. Topoisomerases as targets for cancer therapy. Biochem. Phar-
macol., 34:4191-4195,1985.
23. Ross, W. E., Rowe, T., Glisson, B., Yalowich, J., and Liu, L. F. Role of
topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
Cancer Res., 44: 5857-5860, 1984.
24. Nelson, E. M., Tewey, K. M., and Liu, L. F. Mechanism of antitumor drug
action: poisoning of mammalian DNA topoisomerase II on DNA by an
antitumor drug m-AMSA. Proc. Nati. Acad. Sci. USA, 81:1361-1365,1984.
25. Tewey, K. M., Rowe, T. C, Yang, L., Halligan, B. D., and Liu, L. F.
Adriamycin-induced DNA damage mediated by mammalian DNA topoisom
erase II. Science (Wash. DC), 226: 466-468, 1984.
26. Rowe, T. C., Chen, G. L., Hsiang, Y. H., and Liu, L. F. DNA damage by
antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer
Res., Â«.-2021-2026, 1986.
27. Ross, W. E., Glaubiger, D. L., and Kohn, K. W. Protein-associated DNA
breaks in cells treated with Adriamycin or ellipticine. Biochim. Biophys.
Acta, 519: 23-30, 1978.
28. Bradley, M. O., and Kohn, K. W. X-ray-induced DNA double-strand break
production and repair in mammalian cells as measured by neutral niter
elution. Nucleic Acids Res., 7: 793-804, 1979.
29. Pommier, Y., Schwartz, R. E., Zwelling, L. A., and Kohn, K. W. Effects of
DNA intercalating agents on topoisomerase II induced DNA strand cleavage
in isolated mammalian cell nuclei. Biochemistry, 24: 6406-6410,1985.
30. Minford, J., Pommier, Y., Filipski, J., Kohn, K. W., Kerrigan, D., Mattern,
M., Michaels, S., Schwartz, R., and Zwelling, L. A. Isolation of intercalator-
dependent protein-linked DNA strand cleavage activity from cell nuclei and
identification as topoisomerase II. Biochemistry, 25:9-16, 1986.
31. Pommier, Y., Schwartz, R. E., Zwelling, L. A., Kerrigan, D., Mattern, M.
R. Charcosset, J. Y., Jacquemin-Sablon, A., and Kohn, K. W. Reduced
formation of protein-associated DNA strand breaks in Chinese hamster cells
resistant to topoisomerase II inhibitors. Cancer Res., 46:611-616, 1986.
32. Pommier, Y., Kerrigan, D., Schwartz, R. E., Swack, J. A., and McCurdy, A.
Altered DNA topoisomerase II activity in Chinese hamster cells resistant to
topoisomerase II inhibitors. Cancer Res., 46: 3075-3081,1986.
33. Capranico, G., Dasdia, T., and Zunino, F. Comparison of doxorubicin-
induced DNA damage in doxorubicin-sensitive and -resistance P388 murine
leukemia cells. Int. J. Cancer, 37:227-231, 1986.
34. Glisson, B., Gupta, R., Hodges, P., and Ross, W. Cross-resistance to inter
calating agents in an epipodophyllotoxin-resistant Chinese hamster ovary
cell line: evidence for a common intracellular target. Cancer Res., 46:1939-
1942, 1986.
35. Odaimi, M., Anderson, B. S., McCredie, K. B., and Heran, M. Drug sensitiv
ity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-/n-anisi-
dide-resistant subline of HL-60 human leukemia. Cancer Res., 46: 3330-
3333, 1986.
36. Robson, C. N., Hoban, P. R., Harris, A. L., and Hickson, I. D. Cross
sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive
Chinese hamster ovary cell lines. Cancer Res., 47: 1560-1565, 1987.
37. Per, S. R., Mattern, M. R., Mirabelli, C. K., Drake, F. H., Johnson, R. K.,
and Crooke, S. T. Characterisation of a subline of P388 leukemia resistant
to amsacrine: evidence of altered topoisomerase II function. Mol. Pharma-
col., 32:17-25, 1987.
38. Goldenberg, G. J., Wang, H., and Blair, G. W. Resistance to Adriamycin:
relationship of cytotoxicity to drug uptake and DNA single- and double-
strand breakage in cloned cell lines of Adriamycin-sensitive and -resistant
P388 leukemia. Cancer Res., 46: 2978-2983, 1986.
39. Deffie, A. M., Alam, T., Seneviratne, C., Beenken, S. W., Batra, J. K., Shea,
T. C., Henner, W. D., and Goldenberg, G. J. Multifactorial resistance to
Adriamycin: relationship of DNA repair, glutathione transferase activity,
drug efflux and P-glycoprotein in cloned cell lines of Adriamycin-sensitive
and -resistant P388 leukemia. Cancer Res., 48: 3595-3602, 1988.
40. Halligan, B. D., Davis, J. L., Edwards, K. A., and Liu, L. F. Intra- and
intermolecular strand transfer by Hel.a DNA topoisomerase I. J. Biol.
Chem., 257: 3995-4000, 1982.
41. ManiÃ¢tis. T., Fritsch, E. F., and Sambrook, J. Molecular Cloning: a Labo
ratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory,
pp. 545, 1982.
42. Bradford, M. M. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem., 72: 248-254,1976.
43. Marini, J. C., Miller, K. G., and Englund, P. T. Decatenation of kinetoplast
DNA by topoisomerases. J. Biol. Chem., 255:4976-4979, 1980.
44. Markovits, J., Pommier, Y., Mattern, M. R., Esnault, C., Roques, B. P.,
LePecq, J. B., and Kohn, K. W. Effects of bifunctional antitumor intercalator
ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisom
erase II. Cancer Res., 46: 5821-5826, 1986.
45. Laemmli, U. K. Cleavage of structural proteins during the assembly of the
head of the bacteriophage T4. Nature (Lond.), 227:680-682, 1970.
46. Towbin, H., Staehlin, T., and Gordon, J. Electrophoretic transfer of proteins
from polyacrylamide gels to nitrocellulose sheets: procedure and some appli
cations. Proc. Nati. Acad. Sci. USA, 76:4350-4354, 1979.
47. Zwelling, L. A. DNA topoisomerase II as a target of antineoplastic drug
therapy. Cancer Metastasis Rev., 4: 263-276, 1985.
48. Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R.,
Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., Crook, S. T.,
and Mirabelli, C. K. Purification of topoisomerase II from amsacrine-resist-
ant P388 leukemia cells. J. Biol. Chem., 262: 16739-16747,1987.
49. Halligan, B. D., Edwards, K. A., and Liu, L. F. Purification and character
isation of a type II DNA topoisomerase from bovine calf thymus. J. Biol.
Chem., 260: 2475-2482, 1985.
50. Schomburg, U., and Grosse, F. Purification and characterization of DNA
topoisomerase II from calf thymus associated with polypeptides of 175 and
150 kDa. Eur. J. Biochem., 760:451 -457, 1986.
62
